100 related articles for article (PubMed ID: 12538509)
1. New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation.
Lee AV; Schiff R; Cui X; Sachdev D; Yee D; Gilmore AP; Streuli CH; Oesterreich S; Hadsell DL
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):516S-23S. PubMed ID: 12538509
[TBL] [Abstract][Full Text] [Related]
2. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.
Johnston SR; Head J; Pancholi S; Detre S; Martin LA; Smith IE; Dowsett M
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):524S-32S. PubMed ID: 12538510
[TBL] [Abstract][Full Text] [Related]
3. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
4. [Future perspectives. From basic research to the development of new therapies aimed at the inhibition of the different stages of signal transduction: applications in breast cancer].
Campone M; Kerbrat P; Roché H; Bennouna J; Cuillière JC; Le Mevel B; Fumoleau P
Bull Cancer; 2003 Oct; 90(10):851-64. PubMed ID: 14706914
[TBL] [Abstract][Full Text] [Related]
5. Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.
Gururaj AE; Rayala SK; Vadlamudi RK; Kumar R
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1001s-1007s. PubMed ID: 16467116
[TBL] [Abstract][Full Text] [Related]
6. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations.
Johnston SR
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):889s-99s. PubMed ID: 15701883
[TBL] [Abstract][Full Text] [Related]
7. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
8. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
Xu H; Washington S; Verderame MF; Manni A
Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
[TBL] [Abstract][Full Text] [Related]
9. Parallel signaling pathways in endothelin-1-induced proliferation of U373MG astrocytoma cells.
He S; Dibas A; Yorio T; Prasanna G
Exp Biol Med (Maywood); 2007 Mar; 232(3):370-84. PubMed ID: 17327470
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance.
Johnston SR
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S145-57. PubMed ID: 16113091
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment.
Roussidis AE; Karamanos NK
In Vivo; 2002; 16(6):459-69. PubMed ID: 12494890
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Massarweh S; Schiff R
Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
[TBL] [Abstract][Full Text] [Related]
13. Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk.
Massarweh S; Schiff R
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S15-24. PubMed ID: 17259554
[TBL] [Abstract][Full Text] [Related]
14. G-protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation.
Gavi S; Shumay E; Wang HY; Malbon CC
Trends Endocrinol Metab; 2006 Mar; 17(2):48-54. PubMed ID: 16460957
[TBL] [Abstract][Full Text] [Related]
15. Targeting signal transduction pathways in colorectal cancer--more than skin deep.
Cohen SJ; Cohen RB; Meropol NJ
J Clin Oncol; 2005 Aug; 23(23):5374-85. PubMed ID: 15998904
[TBL] [Abstract][Full Text] [Related]
16. Intracellular signal transduction pathway proteins as targets for cancer therapy.
Adjei AA; Hidalgo M
J Clin Oncol; 2005 Aug; 23(23):5386-403. PubMed ID: 15983388
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between signaling pathways of adrenoreceptors and signal transducers and activators of transcription 3 (STAT3) in heart.
Gong KZ; Zhang H; Du JH; Zhang YY
Acta Pharmacol Sin; 2007 Feb; 28(2):153-65. PubMed ID: 17241516
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer.
Tao Y; Pinzi V; Bourhis J; Deutsch E
Nat Clin Pract Oncol; 2007 Oct; 4(10):591-602. PubMed ID: 17898809
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of growth factor signalling.
Wakeling AE
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S183-7. PubMed ID: 16113095
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase inhibitors as a therapeutic modality.
Levitzki A
Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
